Tilray Brands Consolidates its Global Medical Offering into Tilray Medical, a Comprehensive Portfolio of Brands and Products
08 Februar 2022 - 1:00PM
Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX:
TLRY), a leading global cannabis-lifestyle and consumer packaged
goods company inspiring and empowering the worldwide community to
live their very best life, today announced the launch of Tilray
Medical, a global medical platform that unifies the Company's
medical cannabis brands under one strategy, mission, and
vision.
Denise Faltischek, Head of International and
Chief Strategy Officer, said, "Tilray is the global leader in the
advancement of cannabinoid-based medicine, with a focus on
providing research-backed medical cannabis products to physicians,
pharmacies, and patients. By unifying the global medical divisions
of Tilray and Aphria under a cohesive strategy and mission, Tilray
Medical emerges as the premier global supplier of a portfolio of
high-quality, effective medical cannabis brands and products for
patients in need around the world."
Under the Tilray Medical consolidation plan,
patients in Canada will have the broadest access to our medical
cannabis brands and product choices globally, including Tilray,
Aphria, Broken Coast, and Symbios. Subject to local regulatory
approvals, Tilray Medical's global portfolio of medical cannabis
products includes high-quality and GMP-certified flower, oils,
vapes, edibles, and topicals. Looking ahead, Tilray Medical will
continue to expand its offering to patients worldwide.
About Tilray
Medical Tilray Medical is dedicated to transforming
lives and fostering dignity for patients in need through safe and
reliable access to a global portfolio of medical cannabis brands,
including Tilray, Aphria, Broken Coast, and Symbios. Tilray grew
from being one of the first companies to become an approved
licensed producer of medical cannabis in Canada to building the
first GMP-certified cannabis production facilities in Europe, first
in Portugal and later in Germany. Today, Tilray Medical is one of
the biggest suppliers of medical cannabis brands to patients,
physicians, hospitals, pharmacies, researchers, and governments, in
20 countries and across five continents.
For more information on Tilray Medical, visit
Tilray Medical Canada, Tilray Medical Australia, Tilray Medical
Australia-New Zealand, Tilray Medical Europe
About Tilray Brands
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY),
is a leading global cannabis-lifestyle and consumer packaged goods
company with operations in Canada, the United States, Europe,
Australia, and Latin America that is changing people's lives for
the better – one person at a time. Tilray Brands delivers on this
mission by inspiring and empowering the worldwide community to live
their very best life and providing access to products that meet the
needs of their mind, body, and soul while invoking wellbeing.
Patients and consumers trust Tilray Brands to deliver a cultivated
experience and health and wellbeing through high-quality,
differentiated brands and innovative products. A pioneer in
cannabis research, cultivation, and distribution, Tilray’s
unprecedented production platform supports over 20 brands in over
20 countries, including comprehensive cannabis offerings,
hemp-based foods, and craft beverages.
For more information on how we open a world of
wellbeing, visit www.Tilray.com.
Forward-Looking Statements
Certain statements in this communication that
are not historical facts constitute forward-looking information or
forward-looking statements (together, “forward-looking statements”)
under Canadian securities laws and within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, that are intended
to be subject to the “safe harbor” created by those sections and
other applicable laws. Forward-looking statements can be identified
by words such as “forecast,” “future,” “should,” “could,” “enable,”
“potential,” “contemplate,” “believe,” “anticipate,” “estimate,”
“plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and
the negative of these terms or similar expressions, although not
all forward-looking statements contain these identifying words.
Certain material factors, estimates, goals, projections or
assumptions were used in drawing the conclusions contained in the
forward-looking statements throughout this communication.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: expectations regarding
the performance and scale of the Company, including Tilray Medical;
and the Company’s ability to expand its offering to patients
worldwide, including via Tilray Medical . Many factors could cause
actual results, performance or achievement to be materially
different from any forward-looking statements, and other risks and
uncertainties not presently known to the Company or that the
Company deems immaterial could also cause actual results or events
to differ materially from those expressed in the forward-looking
statements contained herein. For a more detailed discussion of
these risks and other factors, see the most recently filed annual
information form of Tilray and the Annual Report on Form 10-K (and
other periodic reports filed with the SEC) of Tilray made with the
SEC and available on EDGAR. The forward-looking statements included
in this communication are made as of the date of this communication
and the Company does not undertake any obligation to publicly
update such forward-looking statements to reflect new information,
subsequent events or otherwise unless required by applicable
securities laws.
Contacts:
Tilray Brands:Berrin Nooratanews@tilray.com
InvestorsRaphael
Gross203-682-8253Raphael.Gross@icrinc.com
Tilray Brands (TSX:TLRY)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Tilray Brands (TSX:TLRY)
Historical Stock Chart
Von Apr 2023 bis Apr 2024